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Endocrinology guidelines for diagnosing insulin resis-
tance syndrome. METHODS: A conﬁrmatory factor
analysis was performed using EQS Multivariate Software
Version 5.7b with maximum likelihood estimation.
Hypertension, obesity, insulin resistance, cholesterol, and
hyperlipidemia were the latent factors studied. RESULTS:
Cholesterol was not signiﬁcantly associated (p < 0.05)
with either obesity (r = 0.015) or insulin resistance (r =
-0.042), giving further support to the possibility of mul-
tiple risk factors for predicting coronary heart disease in
addition to elevated LDL cholesterol. Signiﬁcant correla-
tions (p < 0.05) were noted between obesity and hyper-
lipidemia (r = 0.583), obesity and insulin resistance (r =
0.899), and insulin resistance and hyperlipidemia (r =
0.928). CONCLUSION: These associations are discussed
in the context that the average patient did not meet Adult
Treatment Panel III deﬁned criteria for metabolic syn-
drome. We suggest that more stringent guidelines such 
as those suggested by the American College of Endo-
crinology may be necessary to identify and diagnose the
pathophysiologic risk factors involved in the metabolic
syndrome. One suggestion may be to include an oral
glucose tolerance test to help in evaluation of insulin 
resistance. More stringent cut-offs for abnormal values of
triglycerides and HDL cholesterol may also be required.
We also suggest that research of the metabolic syndrome
may be better accomplished by focusing on individual
physiologic components rather than focusing on one
single etiology to quantify, which is an approach that has
been taken in previous research.
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OBJECTIVES: As part of an outcomes program on
smoking cessation, we thought it relevant to evaluate in
smokers under 25 years of age the obstacles to cessation,
the level of dependency, the knowledge of tobacco depen-
dency and the propensity to pay for cessation treatment.
METHOD: For this pilot phase, an anonymous ques-
tionnaire was distributed in the Etudiant supplement 
of a French regional weekly newspaper (Tarn Libre).
RESULTS: Obstacle to cessation: lack of willpower
(51%), enjoyment of smoking (32%), force of habit
(46%) The level of dependency on tobacco was evaluated
using the Fagerström test: 48% had low dependency,
48% moderate dependency and 2% high dependency. In
general, our sample population had a good general
knowledge and understanding of tobacco use (number of
premature deaths per year, percentage of smokers in
France, cost of tobacco for health insurance). Average
daily tobacco expenses were €2.3 (roughly corresponding
to an average consumption of 10 cigarettes/day), and the
subjects declared themselves ready to pay around €83 to
stop smoking (€157 in older adults). This ﬁgure is rela-
tively low and is explained without doubt by an under-
estimation of the potential risks of tobacco dependency.
CONCLUSION: Young people are a population whose
dependency level is mainly low or moderate, a fact that
enables (with appropriate but generalized mobilization
(doctor, educator, pharmacist, family)) a smoking cessa-
tion attempt to succeed.
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OBJECTIVES: NCEP ATP III guidelines expanded indi-
cations for intensive cholesterol-lowering therapy by
focusing on primary prevention in individuals with mul-
tiple risk factors. This study examined the impact of
guidelines on pharmacologic treatment patterns in 
individuals at high risk for cardiovascular disease. A 
retrospective database study was conducted in a large
multi-site managed care organization. Speciﬁc objectives
were to: 1) determine prevalence of high-risk members;
2) assess existing LDL testing patterns; 3) assess patterns
of medication treatment: 4) assess the impact of ATP III
guidelines on lipid outcome; and 5) examine medication
possession ratios—Days supply of statin / (End date of
study—First prescription date) for goal achievers versus
non-achievers. METHODS: Medical, laboratory and
pharmacy records of members aged 18 years and over and
continuously enrolled for 30 months were reviewed to
identify individuals with a diagnosis of coronary artery
disease (CAD) or risk equivalent (one or more of the 
following: peripheral artery disease, abdominal aortic
aneurysm, symptomatic carotid artery disease, diabetes).
RESULTS: Of 422,914 members who met age and enroll-
ment criteria, 16,036 (3.8%) were high risk. 38.4% of
high-risk members had LDL tests during the observation
period. 38.1% of high-risk members received a prescrip-
tion for a cholesterol-lowering drug. The percentage 
of high-risk members that reached NCEP ATP Goal 
<100mg/dl LDL was 34.7%. Members with anti-
lipidemic prescriptions were signiﬁcantly more likely to
reach ATP III goal (42.2% vs. 26.6%) (measured by Test
of Proportion Z = 12.78). A Wilcoxon Rank Sum test
indicated that Risk and Risk EQ Ss who reached goal
were signiﬁcantly more likely to have a high Possession
Ratio than those who did not reach goal. CONCLU-
SIONS: Managed care provides numerous opportunities
to improve cardiovascular health through identiﬁcation
of high risk members, educating physicians on NCEP ATP
III guidelines; more aggressive testing and treatment,
patient compliance counseling and monitoring of goal
performance.
